- Home
- GXAI vs SNGX Comparison
GXAI vs SNGX Comparison
Compare GXAI & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GXAI | SNGX |
|---|---|---|
| Founded | 2021 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 12.0M |
| IPO Year | 2022 | 2006 |
Fundamental Metrics
Financial Performance| Metric | GXAI | SNGX |
|---|---|---|
| Price | $1.39 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 11.4M | 108.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,027.00 | ★ $119,371.00 |
| Revenue This Year | $42,959.35 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1473.05 | N/A |
| 52 Week Low | $1.00 | $1.02 |
| 52 Week High | $2.96 | $6.23 |
Technical Indicators
Market Signals| Indicator | GXAI | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 51.20 | 52.45 |
| Support Level | $1.11 | $1.19 |
| Resistance Level | $1.39 | $1.22 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 23.72 | 60.27 |
Price Performance
Historical ComparisonAbout GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).